1. Twells LK, Gregory M, Reddigan J, Midodzi WK. Current and predicted prevalence of obesity in Canada: a trend analysis. CMAJ Open. 2014;2:E18-26. |
|
2. Whitlock G, Lewington S et al. Body-mass index and causespecific mortality in 900.000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-96. [DOI via Crossref] |
|
3. Safer Healthcare. Venous Thromboembolism Prevention: Getting Started Kit May 2012 (cited 2015 Jan 30) available from: www.saferhealthcarenow.ca |
|
4. Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther. 2010;8:1711-21. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
5. Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage B. Efficacy and safety of high-dose prophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111:88-93. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
6. Mahan CE, Spyropoulos AC. ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients. Am J Health-System Pharm. 2012;69:2174-90. [DOI via Crossref] |
|
7. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. Chest. 2012;141;e195S-e226S. |
|
8. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-9. [DOI via Crossref] [Pubmed] |
|
9. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med.1999;341:793-80. [DOI via Crossref] [Pubmed] |
|
10. Cohen T, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. Br Med J. 2006;332:325-29. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
11. Nutescu EA, Spinler SA, Wittlowsky.Low-molecular weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43):1064-83. |
|
12. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thrombo embolism: the Padua Prediction Score. J Thromb Haemost. 2010;8:2450-57. [DOI via Crossref] [Pubmed] |
|
13. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-94. [DOI via Crossref] [Pubmed] |
|
14. Linkins LA ,Dans AL Moores LK , Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin induced thrombocytopenia. Antithrombotic therapy and prevention of thrombosis, 9th ed American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141;e495S-e530S. |
|
15. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification 2002. New York (NY): National Kidney Foundation. [cited 2015 May 21]. Available from http://www2.kidney.org/professionals/KDOQI/guidelines |
|
16. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003;14:341-346. [DOI via Crossref] [Pubmed] |
|
17. Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AGG et al. Efficacy and safety of fixed low dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients. Arch Intern Med. 2005;165:341-45. [DOI via Crossref] [Pubmed] |
|
18. Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111:88-93. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
19. Flanders SA, Greene T, Grant P, Kaatz S, et al. Hospital performance for pharmacological venous thromboembolism prophyalxis and rate of venous thromboembolism a cohort study, JAMA Intern Med 2015;174:1577-84. |
|
20. Caprini JA. Thrombosis risk assessment as guide to quality patient care. Dis Mon. 2005;51:70-8. [DOI via Crossref] [Pubmed] |
|
21. Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophyalxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011;155:602-15. [DOI via Crossref] [Pubmed] |
|